Type 2 diabetes (T2D) is a complex disease resulting from lifestyle, environmental, and genetic factors. Prevalence rates differ across ethnicities, with the higher rates occurring in African Americans at a prevalence of 18% ([@B1]). Although multiple genetic risk variants for T2D have been identified in predominantly European-derived populations ([@B2]--[@B6]), prior studies have shown little evidence for association of these single nucleotide polymorphisms (SNPs) in African Americans other than *TCF7L2* variants ([@B7]--[@B9]). Several risk assessment studies have been performed to assess the cumulative effect of multiple T2D "risk" variants on diabetes incidence ([@B10]--[@B17]), although few have included African Americans ([@B11],[@B16]) and none have focused solely on this population.

We evaluated the cumulative risk effect of 17 index variants in a well-characterized sample of African American T2D case subjects and nondiabetic control subjects.

RESEARCH DESIGN AND METHODS {#s5}
===========================

A total of 2,652 African Americans with T2D and 1,393 nondiabetic control subjects were evaluated. Only individuals with complete age data and proportions of African ancestry \>0.50 were included. Case subjects consisted of DNA samples from 2,652 self-described African American individuals with T2D, including 1,502 ascertained through having end-stage renal disease (T2D-ESRD). Control subjects included DNA samples from 1,393 nondiabetic African Americans. Ascertainment criteria and recruitment methods have been described ([@B18]). Recruitment and sample collection procedures were approved by the Wake Forest School of Medicine Institutional Review Board, and written informed consent was obtained from all participants. Subjects were unrelated, self-described African Americans born in North Carolina, South Carolina, Georgia, Virginia, or Tennessee. Subjects with T2D-ESRD were recruited from dialysis facilities.

T2D was diagnosed as diabetes development after the age of 25 years without prior diabetic ketoacidosis. In addition, T2D-ESRD case subjects met at least one of the following criteria for inclusion: *1*) T2D diagnosed ≥5 years before initiating renal replacement therapy, *2*) background or greater diabetic retinopathy, or *3*) ≥100 mg/dL proteinuria on urinalysis in the absence of other causes of nephropathy (set 1 case subjects). Subjects with T2D without evidence of nephropathy were recruited from medical clinics, churches, health fairs, and community resources using the above criteria (set 2 case subjects). African American control subjects without a current diagnosis of diabetes or renal disease were recruited from the community and internal medicine clinics (set 1 and 2 control subjects). DNA extraction was performed using the PureGene system (Gentra Systems, Minneapolis, MN).

Genotyping and quality control {#s6}
------------------------------

Seventeen index SNPs with prior compelling evidence of association with T2D in European-derived populations ([@B2]--[@B6]) were genotyped in 2,652 African Americans with T2D (1,502 with T2D-ESRD, 1,150 with T2D lacking nephropathy) and in 1,393 nondiabetic control subjects. SNPs were genotyped on the Affymetrix Genome-wide Human SNP array 6.0 (Affy 6.0) at the Center for Inherited Disease Research (CIDR) as part of a Genome Wide Association Study or by using the MassARRAY genotyping system with PCR primers designed using MassARRAY Design 3.4 software (Sequenom, San Diego, CA). For 913 T2D-ESRD case subjects and 826 control subjects, 12 of 17 SNPs were genotyped on the Affy 6.0, methods and quality control for which have been previously described ([@B18]). SNPs had \<5% missing data, and there was no significant difference in missing data between case and control subjects. Forty-six blind duplicates were included in genotyping and had a concordance rate of 99.6%. Genotyping of remaining SNPs and samples was done on the iPLEX Sequenom MassARRAY platform (Sequenom). Genotyping efficiency exceeded 93.5%, and the 95 blind duplicate samples included in genotyping had a concordance rate of \>99.5%. Hardy-Weinberg proportions were \>0.0005 in all case and control subjects analyzed.

Admixture estimates {#s7}
-------------------

Ancestral allele proportions were estimated from allele frequencies of 70 ancestry informative markers ([@B19]) genotyped in 44 Yoruba Nigerians and 39 European Americans. Individual ancestral proportions were calculated for each subject using the frequentist estimation of individual ancestry proportion (FRAPPE) program ([@B20]) under a two-population model. Individuals with proportions of African ancestry \<0.50 were excluded from analyses. Admixture estimates were used as covariates in all statistical analyses.

Statistical analysis {#s8}
--------------------

### Individual SNP association analyses. {#s9}

The 17 SNPs were individually tested for association with T2D in the overall cohort using a logistic regression model and then evaluated individually for association with T2D by disease type in sets 1 and 2 using the SNPGWA program ([www.phs.wfubmc.edu](http://www.phs.wfubmc.edu)). The additive genetic model is reported here. Set 1 and 2 results were subsequently combined in a meta-analysis. The inverse variance weighted method was implemented in METAL (<http://www.sph.umich.edu/csg/abecasis/metal/>) to determine the overall association of each index variant with T2D. Because of the statistical significance and potential confounding effects, all analyses were adjusted for age (*P* = 5.6 × 10^−119^), sex (*P* = 1.3 × 10^−4^), and percentage of African ancestry (*P* = 1.6 × 10^−4^). In evaluating individual variants for association with T2D, a supplemental analysis was performed that also adjusted for BMI. Multiple comparison correction was not performed owing to the a priori hypothesis of association between the variants examined and T2D and the primary hypothesis of a single cumulative risk for these loci.

### Cumulative risk scores. {#s10}

Risk allele loads were initially determined in an unweighted approach where the number of risk variants carried by an individual at each SNP was summed to create a cumulative risk score based on the reported risk allele. A second risk score was calculated by a weighted method in which published effect sizes (natural logarithm of odds ratio \[OR\]) for each risk variant (identified in predominantly European studies) were used to adjust for the relative contribution of each SNP in the cumulative risk score calculation. In both methods, missing values were replaced with the average-risk allele load at each SNP (\<4.5% missing data for all SNPs), and cumulative scores were rounded to the nearest value; the maximum possible score in each analysis was 34. Risk score differences between case and control subjects were compared using a Wilcoxon rank sum test.

### Cumulative risk assessment. {#s11}

Cumulative risk scores in the unweighted and weighted analyses were grouped into nine bins: ≤17, 18, 19, 20, 21, 22, 23, 24, and ≥25. Binned risk scores of case and control subjects were compared using a Wilcoxon rank sum test. Bins from the unweighted and weighted analyses were both tested for association with T2D using logistic regression analysis, adjusting for the covariates of African ancestry, age, and sex. Binned risk scores were modeled as ordinal categoric variables and, in a separate analysis, as nine nominal categories; the latter is less parsimonious but allows for greater flexibility (i.e., nonlinearity) in the estimation of the individual bin risk score effects. A model was computed that tested for evidence of a departure from linearity in the bin risk score effect on T2D affection status. Additional analyses included the number of *TCF7L2* rs7903146 risk variants as covariates in the logistic regression model. This model estimates and tests the effect of the other loci after accounting for the strong *TCF7L2* influence on risk of T2D. Theoretically, this latter model will have greater statistical power to detect the effects of the other loci.

RESULTS {#s12}
=======

Study samples {#s13}
-------------

Clinical characteristics of the study samples are reported in [Table 1](#T1){ref-type="table"}. The case group in set 1 had more women than the control group. The mean age at enrollment for the T2D-ESRD group was higher (*P* \< 0.05), but the age of onset of T2D in the case subjects was \>7 years earlier than the age of enrollment for control subjects. Mean BMI was not significantly different between T2D-ESRD case and nondiabetic control subjects (*P* = 0.19). Set 2 case subjects also included a higher percentage of women. Mean age at enrollment for the T2D group was higher (*P* \< 0.05); the mean BMI for T2D case subjects was higher than for control subjects (*P* \< 0.05). Overall, the samples have characteristics that reflect the general population of African Americans in the southeast. The mean (SD) African ancestry proportions in the 1,502 T2D-ESRD case subjects, 1,150 T2D case subjects, and 1,393 combined control subjects were 0.79 ± 0.10, 0.78 ± 0.10, and 0.78 ± 0.09, respectively, as estimated by the frequentist estimation of individual ancestry proportion program.

###### 

Clinical characteristics of study samples
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Analysis of individual index variants {#s14}
-------------------------------------

Risk allele frequencies and individual SNP association results are reported in [Table 2](#T2){ref-type="table"}. When the 2,652 T2D case subjects and 1,393 control subjects were combined, frequencies of risk alleles ranged from 8.64 to 99.97%. Notably, we observed an association of rs7903146 in *TCF7L2*(OR 1.38 \[95% CI 1.23--1.54\], *P* = 1.25 × 10^−8^). In addition, rs10010131 in *WFS1*(OR 1.13, *P* = 0.029), rs10946398 in *CDKAL1* (OR 1.14, *P* = 0.014), and rs864745 in *JAZF1*(OR 1.20, *P* = 2.30 × 10^−3^) were associated with directions of association consistent with prior reports in European-derived samples. SNP rs4607103 in *ADAMTS9* was also associated (*P* = 2.40 × 10^−3^); however, the direction of association was opposite that reported in a European sample ([@B5]) (OR 0.84 in this analysis). Results of an additional analysis adjusting for BMI were comparable ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0957/-/DC1)).

###### 

Individual SNP associations by logistic regression analysis in entire cohort

![](287tbl2)

SNPs were evaluated in case groups (sets 1 and 2) and subsequently combined in a meta-analysis to determine if associations differed between the overall and individual analyses ([Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0957/-/DC1)). The *TCF7L2* variant rs7903146 was associated in sets 1 and 2. In set 1, rs4607103 in *ADAMTS9* was associated; however, the effect was in the opposite direction of that reported in a European sample ([@B5]). In set 2, rs10946398 in *CDKAL1* was associated, as was rs864745 in *JAZF1*. In the meta-analysis, results were consistent with the combined analysis (described above) ([Table 2](#T2){ref-type="table"}); rs10010131 in *WFS1*, rs10946398 in *CDKAL1*, rs864745 in *JAZF1*, and rs7903146 in *TCF7L2* replicated association with risk, whereas rs4607103 in *ADAMTS9* replicated association in the opposite direction of effect of that previously reported in a European sample ([@B5]).

Cumulative risk score {#s15}
---------------------

Unweighted and weighted cumulative risk scores were evaluated in the overall cohort. [Figure 1*A*and *B*](#F1){ref-type="fig"} show the percentage of T2D case and nondiabetic control subjects plotted by the cumulative risk score of each individual; values were significantly different when scores were determined by both unweighted and weighted methods (*P* \< 0.005 for both analyses). [Figure 1*C* and *D*](#F1){ref-type="fig"} show binned distributions of cumulative risk scores determined by unweighted and weighted methods in T2D case and nondiabetic control subjects. [Figure 1*C*](#F1){ref-type="fig"} shows that the nondiabetic control group had higher percentages of individuals carrying lower-risk allele loads (\<21); whereas the T2D groups generally had greater percentages of individuals carrying higher-risk allele loads. [Figure 1*D*](#F1){ref-type="fig"} highlights the more pronounced distribution differences in risk allele bins between the two groups. Differences in binned distributions for both unweighted and weighted analyses were significant (*P* \< 0.005).

![Distribution of cumulative risk allele loads in T2D case subjects (black bars) and nondiabetic control subjects (gray bars) by risk score (*A*and *B*) and by bin (*C*and *D*) in unweighted analysis (*A*and *C*) and in weighted analysis by published effect size (*B*and *D*).](287fig1){#F1}

Cumulative risk assessment {#s16}
--------------------------

The OR and 95% CI for each of the nine bins assessed by the full logistic regression model and the model with adjustment for rs7903146 are represented in [Fig. 2*A*](#F2){ref-type="fig"} (unweighted) and [Fig. 2*B*](#F2){ref-type="fig"} (weighted); results are summarized in [Supplementary Table 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0957/-/DC1). There was an increase in the OR with an increase in risk allele category. There was no evidence of departure from a linear trend in the association of the number of risk alleles and disease (*P* = 0.71). In a model in which data were reanalyzed, treating the risk allele categories as a continuous variable, there was evidence of an association between cumulative risk allele load and disease status in the unweighted and weighted analyses (unweighted OR 1.04 \[95% CI 1.01--1.08\], *P* = 0.011; weighted 1.06 \[1.03--1.10\], *P* = 8.10 × 10^−5^). In both types of analysis (i.e., nominal and ordinal categories for the count of risk alleles), association was no longer significant after adjusting for the number of *TCF7L2* risk variant rs7903146: nominal analysis results ([Supplementary Table 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0957/-/DC1) and [Fig. 2*A* and *B*](#F2){ref-type="fig"}); ordinal analysis results (unweighted 1.02 \[0.98--1.05\], *P* = 0.33; weighted 1.02 \[0.98--1.06\], *P* = 0.40).

![The OR and 95% CI (range bars) for each of the nine bins assessed in the cumulative risk assessment using the full logistic regression model (black diamonds) and the model with adjustment for rs7903146 (gray squares) are represented from unweighted (*A*) and weighted (*B*) analyses. All models were adjusted for age, sex, and proportion of African ancestry.](287fig2){#F2}

We found no evidence for interaction with age (*P* = 0.20), sex (*P* = 0.59), BMI (*P* = 0.47), or degree of African Ancestry (*P* = 0.74). Recall that only individuals with \>0.50 proportions of African ancestry are included in these analyses.

CONCLUSIONS {#s17}
===========

T2D risk variant associations have been identified in European-derived populations, although the functional variants are not all known. Also, there have been few reports in the high-risk African American population. This study evaluated 17 SNPs that have shown association with risk for T2D in mostly European-derived populations ([@B2]--[@B6]). Five risk variants are nominally associated with T2D in this African American sample, including rs4607103 (*ADAMTS9*), rs10010131 (*WFS1*), rs10946398 (*CDKAL1*), rs864745 (*JAZF1*), and rs7903146 (*TCF7L2*); all risk alleles are consistent with those reported in European-derived samples except for *ADAMTS9*. SNPs rs4607103 (*ADAMTS9*), rs10010131 (*WFS1*), rs10946398 (*CDKAL1*), and rs864745 (*JAZF1*) remained associated when accounting for the presence of *TCF7L2* SNP rs7903146 risk variants, suggesting these are independent loci (data not shown). Inferences were not changed when adjustment for BMI was performed. In addition, this study demonstrated that a genetic risk score based on 17 European-derived T2D-associated risk variants was not predictive of T2D status in African Americans after removing the effects of the important *TCF7L2* risk variant rs7903146.

There are a number of potential explanations for the observed association in the *ADAMTS9* SNP rs4607103 that is in the opposite direction of what was previously described ([@B5]). The actual functional variant in the *ADAMTS9* region is not known, and the rs4607103 SNP may not be the functional variant in this region. It is presumed that rs4607103 is in linkage disequilibrium (LD) with the functional variant in individuals of European descent. An independent mutation may have arisen in African Americans in the *ADAMTS9* region on a different haplotype, resulting in a change in direction of association. In addition, with the exception of rs7903146 in TCF7L2, the evidence for association of other SNPs is modest, and given the number of SNPs, rs4607103 barely meets evidence for association (Bonferroni corrected *P* = 0.0029 vs. *P* = 0.0024 for rs4607103), and the resulting inverse association could be a chance false-positive. In addition, the LD pattern in Africans is sufficiently different from Europeans so that LD relationships in African Americans may be substantially different with a trait-defining variant, thus obscuring the true relationship.

Previous studies assessing European-identified T2D variants have shown little evidence that these SNPs are associated with T2D in African Americans, with the exception of *TCF7L2* variant rs7903146 ([@B7],[@B8],[@B21],[@B22]). This issue is difficult to convincingly address given differences in allele frequency, sample sizes, and attendant power in African American studies ([@B7]). The current analyses tested variants that were also analyzed by Waters et al. ([@B16]) in the Population Architecture Using Genomics and Epidemiology study. Many variants were associated in a pooled analysis of multiple ethnic groups, but results from the African American subset (1,077 case subjects, and 1,469 control subjects) were significant for four variants (rs1801282 in *PPARG*, rs4402960 in *IGF2BP2*, r864745 in *JAZF1*, rs7903146 in *TCF7L2*). The larger sample size evaluated here provides a nominal increase in power compared with prior reports and found an association with SNPs in *ADAMTS9*, *WFS1*, *CDKAL1*, and *JAZF1*, in addition to the well-replicated rs7903146 in *TCF7L2*. An important feature of the analysis reported here is a detailed evaluation of admixture proportions to exclude DNA samples with \<0.50 African ancestry. Admixture was a major influence on our inferences (*P* = 1.6 × 10^−4^) in analysis of these data and was therefore included as a covariate to eliminate potential stratification.

We observed a significant increase in T2D risk with increased risk allele load in analyses using unweighted and weighted methods to generate a risk score. Similar risk score analyses have been performed in other studies, most often in individuals of European descent. We observed similar results (i.e., increased risk with increasing risk allele load) ([@B10]--[@B17]). Two such studies included African Americans and detected an increased risk with increase in risk allele load in their overall samples ([@B11],[@B16]). When analyses were limited to African American individuals, however, results were less significant (if at all) in contrast to European-only and multiethnic samples. Waters et al. ([@B16]) evaluated increased progression to T2D with risk allele load and observed association in a multiethnic cohort and African American subset. Hivert et al. ([@B11]) also observed association between risk allele load and progression to T2D in the Diabetes Prevention Program (DPP) cohort; however, results were not significant when limited to the smaller African American subset. Neither Waters et al. nor the DPP studies accounted for admixture proportions in African American participants.

The major observation here is that removing the most significantly associated variant (rs7903146) from the risk prediction model substantially changed the inferences. Significance was no longer observed in the risk score model after adjustment for the effect of the *TCF7L2* variant. Although risk for T2D increases with increasing risk allele load, similar to Europeans, this was primarily driven by the rs7903146 variant of *TCF7L2.* The other risk variants do not appear to jointly significantly contribute to disease risk because of the lower or insignificant effect of these SNPs.

Previous T2D genetic risk models have failed to be more predictive of disease risk than conventional factors that contribute to risk ([@B10],[@B13],[@B15],[@B23]). In addition, it has been reported that the variants studied here, along with other European T2D "risk" variants, do not explain a significant portion of the racial/ethnic disparities in T2D prevalence, although African Americans on average carry more risk alleles compared with European Americans ([@B16]). Genetic risk models for T2D, such as the one in this study, may not include causal variants and therefore must be regarded carefully ([@B16]). Causal variants or variants in high LD with causal variants for T2D may differ across ethnicities, further complicating the search for genetic contributors to this polygenic disease. Differences in LD architecture encompassing the variants among different populations may help to fine-map the causal variant if shared across ethnicities, as shown in Palmer et al. ([@B8]).

In addition, only 4 of the remaining 16 variants were associated, highlighting that SNPs associated with T2D risk in individuals of European descent may not consistently represent critical risk variants in non-European populations, African Americans in particular. Alternatively, the SNPs we studied may not represent variants in LD with causal variants in this population, supporting the variability of disease-risk architecture across different ethnicities. This effect may be a consequence of ancestral exposure to different selective pressures and/or environments, resulting in the conservation of disease-causing alleles in LD with other genetic variants necessary for survival, such as the case of *APOL-1* risk variants that are protective against trypanosomes that cause African sleeping sickness ([@B24]).

This study represents a comprehensive evaluation of cumulative genetic risk for T2D in a large African American cohort and demonstrates compelling evidence that the *TCF7L2* SNP rs7903146 is the most significant genetic contributor to T2D risk in African Americans. Differences in LD structure and genetic architecture across different ethnic groups, in addition to diverse evolutionary pressures and environmental modifiers, are important factors to consider as the search for genetic variants contributing to T2D in African Americans progresses.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0957/-/DC1>.

See accompanying commentary, p. 193.
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